Upcoming Post-Conference Perspectives: ASH 2021

Rafael Fonseca, MD, shares his excitement for an upcoming AJMC Post-Conferences Perspectives video series covering the 2021 American Society of Hematology annual meeting.

Now Viewing

EP: 1.Upcoming Post-Conference Perspectives: ASH 2021

EP: 2.The MASTER Trial: Frontline Dara-KRd in Newly Diagnosed Multiple Myeloma

EP: 3.Frontline Use of Daratumumab-Based Regimens in Transplant-Ineligible MM

EP: 4.Rescue Isatuximab in Transplant-Ineligible, Treatment Naïve NDMM

EP: 5.Multiple Myeloma: Current Approaches to Frontline Therapy

EP: 6.2-Year Followup Data From the GRIFFIN Trial in Transplant-Ineligible NDMM

EP: 7.Novel Therapy for Multiple Myeloma: Future Directions in Care

EP: 8.How Should MRD Results Be Used? Experts Don’t Necessarily Agree, Dr Ajay Nooka Says

Related Videos

Related Content

Advertisement

February 13th 2025

Rapid IV Isatuximab Could Shift Care Practices in MM

Kyle Munz

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.

February 7th 2025

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

Kyle Munz

The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.

January 25th 2025

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

January 22nd 2025

Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm

Luke Halpern Laura Joszt, MA

January 21st 2025

High Infection Risk in MM: Insights From the Preimmunotherapy Era

Kyle Munz

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.

January 13th 2025

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

Kyle Munz

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

Related Content

Advertisement

February 13th 2025

Rapid IV Isatuximab Could Shift Care Practices in MM

Kyle Munz

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.

February 7th 2025

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

Kyle Munz

The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.

January 25th 2025

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

January 22nd 2025

Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm

Luke Halpern Laura Joszt, MA

January 21st 2025

High Infection Risk in MM: Insights From the Preimmunotherapy Era

Kyle Munz

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.

January 13th 2025

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

Kyle Munz

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.